These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 18815292

  • 1. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.
    J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.
    J Virol; 2016 Jan 13; 90(7):3446-57. PubMed ID: 26763999
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
    Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K.
    PLoS One; 2012 Jan 13; 7(8):e43704. PubMed ID: 22952740
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
    Nyanhete TE, Edwards RJ, LaBranche CC, Mansouri K, Eaton A, Dennison SM, Saunders KO, Goodman D, Janowska K, Spreng RL, Zhang L, Mudrak SV, Hope TJ, Hora B, Bradley T, Georgiev IS, Montefiori DC, Acharya P, Tomaras GD.
    Front Immunol; 2021 Jan 13; 12():670561. PubMed ID: 35003053
    [Abstract] [Full Text] [Related]

  • 11. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR, De Souza MS, Chanbancherd P, Chantakulkij S, Jugsudee A, Loomis-Price LD, Vancott TC, Garner R, Markowitz LE, Brown AE, Birx DL.
    AIDS Res Hum Retroviruses; 2001 Jan 01; 17(1):69-79. PubMed ID: 11177385
    [Abstract] [Full Text] [Related]

  • 12. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R, Tuen M, Liu J, Nàdas A, Pan R, Kong X, Hioe CE.
    Vaccine; 2013 Nov 04; 31(46):5413-21. PubMed ID: 24051158
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    D'Souza MP, Livnat D, Bradac JA, Bridges SH.
    J Infect Dis; 1997 May 04; 175(5):1056-62. PubMed ID: 9129066
    [Abstract] [Full Text] [Related]

  • 14. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.
    Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.
    J Virol; 2009 Sep 04; 83(17):8925-37. PubMed ID: 19553335
    [Abstract] [Full Text] [Related]

  • 15. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M, Weiβ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.
    PLoS One; 2014 Sep 04; 9(5):e97478. PubMed ID: 24828352
    [Abstract] [Full Text] [Related]

  • 16. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.
    Virology; 2009 May 10; 387(2):414-26. PubMed ID: 19298995
    [Abstract] [Full Text] [Related]

  • 17. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV, Dimitrov DS.
    J Virol; 2004 Sep 10; 78(17):9233-42. PubMed ID: 15308718
    [Abstract] [Full Text] [Related]

  • 18. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
    Law M, Cardoso RM, Wilson IA, Burton DR.
    J Virol; 2007 Apr 10; 81(8):4272-85. PubMed ID: 17267498
    [Abstract] [Full Text] [Related]

  • 19. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, Wasi C.
    Viral Immunol; 1996 Apr 10; 9(3):175-85. PubMed ID: 8890476
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.